Realcan Pharmaceutical Group Co (SZSE:002589) Cash-to-Debt

: 1.44 (As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Realcan Pharmaceutical Group Co's cash to debt ratio for the quarter that ended in Sep. 2023 was 1.44.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Realcan Pharmaceutical Group Co could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Realcan Pharmaceutical Group Co's Cash-to-Debt or its related term are showing as below:

SZSE:002589' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16 Med: 0.7 Max: 1.44
Current: 1.44

During the past 13 years, Realcan Pharmaceutical Group Co's highest Cash to Debt Ratio was 1.44. The lowest was 0.16. And the median was 0.70.

SZSE:002589's Cash-to-Debt is ranked better than
55.67% of 97 companies
in the Medical Distribution industry
Industry Median: 0.89 vs SZSE:002589: 1.44

Realcan Pharmaceutical Group Co Cash-to-Debt Historical Data

The historical data trend for Realcan Pharmaceutical Group Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Realcan Pharmaceutical Group Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

0.40

0.77

0.61

1.07

1.36

Realcan Pharmaceutical Group Co Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt																1.03	1.36	1.27	1.44	1.44

Competitive Comparison

For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Realcan Pharmaceutical Group Co Cash-to-Debt Distribution

For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Realcan Pharmaceutical Group Co's Cash-to-Debt falls into.

Realcan Pharmaceutical Group Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Realcan Pharmaceutical Group Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5340.212	/	(3848.167	+	69.93)
	=	1.36

Realcan Pharmaceutical Group Co's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5597.495	/	(3708.523	+	177.362)
	=	1.44

Realcan Pharmaceutical Group Co (SZSE:002589) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Realcan Pharmaceutical Group Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Realcan Pharmaceutical Group Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Realcan Pharmaceutical Group Co (SZSE:002589) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Realcan Pharmaceutical Group Co Ltd (SZSE:002589) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 326, Airport Road, Zhifu District, Shandong Province, Yantai, CHN, 264004

Website

http://www.realcan.cn

Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.

Realcan Pharmaceutical Group Co (SZSE:002589) Headlines

No Headlines